Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol by Indlekofer, Friedrich J. et al.
The final, definitive version of this paper has been published in Journal of 
Psychopharmacology, vol. 23 no. 5, June 2009 by SAGE Publications Ltd. All rights 
reserved. © SAGE Publications Ltd. 
 
Reduced memory and attention performance in a population-based sample of 
young adults with a moderate lifetime use of cannabis, ecstasy and alcohol 
 
 
F. Indlekofer, Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, 
Germany.   
M. Piechatzek, Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, 
Germany.   
M. Daamen, Department of Psychiatry and Psychotherapy, Friedrich Wilhelm University, Bonn, 
Germany.   
C. Glasmacher, Department of Psychiatry and Psychotherapy, Friedrich Wilhelm University, Bonn, 
Germany.   
R. Lieb, Max Planck Institute for Psychiatry, Munich, Germany.   
H. Pfister, Max Planck Institute for Psychiatry, Munich, Germany.   
O. Tucha, School of Psychology, University of Plymouth, Plymouth, Devon, UK.   
K.W. Lange, Department of Experimental Psychology, University of Regensburg, Regensburg, 
Germany.   
H.U. Wittchen, Max Planck Institute for Psychiatry, Munich, Germany; Department of Psychiatry and 
Psychotherapy, University of Dresden, Dresden, Germany.   
C.G. Schütz, Department of Psychiatry and Psychotherapy, Friedrich Wilhelm University, Bonn, 




Abstract   
 
Regular use of illegal drugs is suspected to cause cognitive impairments. Two substances have 
received heightened attention: 3,4- methylenedioxymethamphetamine (MDMA or ‘ecstasy’) and δ- 9-
tetrahydrocannabinol (THC or ‘cannabis’). Preclinical evidence, as well as human studies examining 
regular ecstasy consumers, indicated that ecstasy use may have negative effects on learning, verbal 
memory and complex attentional functions. Cannabis has also been linked to symptoms of inattention 
and deficits in learning and memory. Most of the published studies in this field of research recruited 
participants by means of newspaper advertisements or by using word-of-mouth strategies. Because 
participants were usually aware that their drug use was critical to the research design, this awareness 
may have caused selection bias or created expectation effects. Focussing on attention and memory, 
this study aimed to assess cognitive functioning in a community-based representative sample that was 
derived from a large-scale epidemiological study. Available data concerning drug use history allowed 
sampling of subjects with varying degrees of lifetime drug experiences. Cognitive functioning was 
examined in 284 young participants, between 22 and 34 years. In general, their lifetime drug 
experience was moderate. Participants completed a neuropsychological test battery, including 
measures for verbal learning, memory and various attentional functions. Linear regression analysis 
was performed to investigate the relationship between cognitive functioning and lifetime experience of 
drug use. Ecstasy and cannabis use were significantly related to poorer episodic memory function in a 
dose-related manner. For attentional measures, decrements of small effect sizes were found. Error 
measures in tonic and phasic alertness tasks, selective attention task and vigilance showed small but 
significant effects, suggesting a stronger tendency to experience lapses of attention. No indication for 
differences in reaction time was found. The results are consistent with decrements of memory and 
attentional performance described in previous studies. These effects are relatively small; however, it 
must be kept in mind that this study focussed on assessing young adults with moderate drug use from a 
population-based study.   
 
Key words alcohol; alertness; cannabis; divided attention; ecstasy; flexibility; learning; memory; 
selective attention; vigilance   
 
   
 
Introduction   
 
3,4-Methylenedioxymethamphetamine (MDMA or ‘ecstasy’) is one of the most frequently 
consumed illegal substances among adolescents and young adults. Because of its combination 
of stimulant, euphoric, anxiolytic and ‘entactogenic’ effects (i.e., feelings of closeness and 
reduced inhibition in contact with others), it has become quite popular among attendees of 
rave and techno parties (Dumont and Verkes, 2006). Recent epidemiological surveys in the 
United States and Europe showed lifetime prevalence in young adults (18–30 years) between 
4.7% and 13.0% (Strote, et al., 2002; von Sydow, et al., 2002). In approximately 97.0% of 
cases, ecstasy users report additional use of other drugs (Schuster, et al., 1998), with cannabis, 
stimulants and alcohol being the most prevalent.   
 
The pharmacological effects of ecstasy are mainly mediated by its facilitating effects on the 
cellular release and reuptake inhibition of serotonin (5-HT: reviewed in Green, et al., 2003). 
Reports of possible neurotoxic processes in animal models (Ricaurte, et al., 2000) and in 
humans (McCann, et al., 1998, 2000; Reneman, et al., 2001) have spurred increased research 
interest. Because the precise mechanisms and the extent of neurotoxicity have not been 
entirely elucidated, it is still a topic of intense debate (Morton, 2005; Gouzoulis- Mayfrank 
and Daumann, 2006). Neurotoxic effects cannot be studied experimentally in human subjects; 
hence, researchers have to rely on naturalistic samples of ecstasy users, and use indirect 
measures for the integrity of brain function. Useful techniques include neuroimaging methods, 
such as ligandpositron emission tomography (PET) (Reneman, et al., 2005), and 
neuropsychological assessments of cognitive functions. In recent years, the relationship 
between drug use, especially of illegal drugs, and cognitive functioning has received 
heightened attention (Rogers and Robbins, 2001), particularly in regard to ecstasy. The most 
consistent neuropsychological findings in heavy ecstasy users are subtle deficits in verbal 
learning and memory. Relative to nondrug controls and ecstasy-naive polydrug controls, 
including cannabis users, ecstasy users showed lower performance levels with regard to 
learning and memory (Bolla, et al., 1998; Parrott, et al., 1998; McCann, et al., 1999; Morgan, 
1999; Gouzoulis-Mayfrank, et al., 2000; Croft, et al., 2001; Fox, et al., 2001a; Zakzanis and 
Young, 2001; McCardle, et al., 2004; Yip and Lee, 2005). Reaction time measures typically 
show no differences between ecstasy users and nonusers, although poorer performance in 
more complex attention tasks has also been reported (McCann, et al., 1998; Gouzoulis- 
Mayfrank, et al., 2000; Fox, et al., 2001b; Zakzanis, et al., 2002).   
 
Typically, ecstasy consumers show additional consumption of cannabis (von Sydow, et al., 
2002). Thus, cannabis use is an important confounding factor in studying the effects of 
ecstasy use (Dafters, et al., 2004). Regular heavy cannabis users have been reported to show 
deficits in memory, learning and attention performance, as well as impairments in reaction 
time measures (Solowij, 1998; Pope, et al., 2001; Solowij, et al., 2002; Dafters, et al., 2004). 
Although some of these cannabis-related decrements may be attributable to subacute effects 
of recent cannabis consumption that cease with continued abstinence (Pope, et al., 2001), 
there may be more long-lasting effects on brain function and cognition. In a meta-analytic 
study of longterm cannabis consequences, Grant, et al. (2003) reported slight impairments 
only in memory and learning domain. For simple reaction time measures or attentional tasks, 
these authors did not find systematic decrements of function.   
 
As with ecstasy, cannabis use has been associated with an increased incidence of psychiatric 
disorders. Some authors (e.g., Croft, et al., 2001) have argued that the apparent cognitive and 
psychiatric effects of ecstasy may, at least to some degree, be caused by concomitant cannabis 
misuse. However, empirical data concerning this question are still inconclusive (Gouzoulis-
Mayfrank and Daumann, 2006).   
 
Most users of illegal substances also drink alcohol. Previous research studies primarily 
investigated the cognitive sequelae of chronic and severe alcohol abuse, focussing on sober 
alcoholdependent subjects, recruited from substance abuse treatment programs. Chronic, 
neurotoxic effects of heavy drinking seem to result in functional impairments and atrophic 
changes in several regions of the cerebral cortex, especially in the frontal lobes, which cause 
impairments of executive functioning and memory (e.g., Dao-Castellana, et al., 1998). 
However, the treatment-seeking, alcohol-dependent subjects constitute only a minor portion 
of the alcohol-consuming population (Meyerhoff, et al., 2005). Compared with clinical 
populations recruited from treatment centres, much less is known about the level of cognitive 
function in socially functioning moderate- or heavydrinking populations. It has been argued 
that there may be a continuum of detrimental effects of alcohol on brain function and 
cognition (Parsons, 1998), although systematically trends may only become apparent beyond 
some threshold consumption level of heavy drinking (Parsons and Nixon, 1998). 
Additionally, these subtle deficits may be more detectable with some measurement techniques 
than with others. Neurophysiologic measures suggest a somewhat higher sensitivity than 
common neuropsychological measurements do (Meyerhoff, et al., 2005).   
 
Little is known about the cognitive sequelae of substance abuse in subjects with moderate 
levels of drug use. The present study was designed to investigate the question of whether 
moderate use of ecstasy and cannabis in a population-based sample is associated with reduced 
performance in memory, verbal learning and complex attentional tasks, as suggested by 
research in heavy-consuming populations. The participants were not informed about the aim 
of the present study because this information seems to be a potential contributing factor to 
self-reported adverse effects of ecstasy use (Cole, et al., 2006).   
 
 
Methods and materials   
 
Subjects   
 
Subjects were recruited from a population-based epidemiological sample investigated in the 
‘Early Developmental Stages of Psychopathology’ (EDSP) study. The EDSP study is a 
longitudinal study conducted by the Max Planck Institute for Psychiatry in Munich, Germany. 
From its beginning in 1994, this epidemiological assessment set out to investigate the health 
of adolescents and young adults. Participants in the EDSP study were interviewed up to four 
times with a number of substance use and psychiatric questionnaires, including the Munich 
Composite International Diagnostic Interview (M-CIDI, Pfister and Wittchen, 1995; DIA-X, 
Wittchen and Pfister, 1997). For further description of the EDSP study, see Lieb, et al. (2000, 
2002). A nested case–control design was used. On the basis of the drug history collected in 
the M-CIDI interviews, subjects were subsampled for additional assessments.   
 
The goal was to obtain a subsample consisting of nearly equal numbers of alcohol, cannabis 
and ecstasy users, as well as nonusers. Subjects with a history of any ecstasy use were 
recruited. Furthermore, we recruited participants with a history of cannabis use, which was 
defined as more than five lifetime occasions. None of them had, at any time, a history of 
ecstasy, heroin or cocaine use. A third user group consisted of subjects who had not consumed 
any psychoactive substances, except alcohol. These subjects had to have a lifetime prevalence 
of consuming alcohol on a harmful basis, as defined by an alcohol index with a minimum of 
seven drinks for six or more months on a single occasion. The only additional drug 
experiences allowed was a sampling of cannabis, which was defined as no more than five 
lifetime uses of cannabis. Sampling of cannabis use reported in adults is highly prevalent but 
is not associated with an increased risk of use of illegal substances (Schütz, et al., 1994). The 
last portion of the sample consisted of participants who had never taken any kind of 
psychoactive substance and had no history of harmful alcohol consumption.   
 
Exclusionary criteria for this sample were intravenous drug use and use of cocaine or heroin. 
Because neurocognitive functions were assessed, subjects with a medical history of brain 
diseases or injuries were excluded as well as subjects showing signs of mental retardation or 
psychotic disorders, which could have diminished cognitive performance. Furthermore, 
subjects with urine samples suggestive of recent drug abuse (e.g., cannabis >150 ng/mL) or 
signs of depressed mood (see below) were excluded.   
 
After conducting the most recent EDSP interview, we asked 1652 participants to take part in 
the present study. Of those asked, 701 subjects gave their consent when contacted by staff 
members of the current investigation, 359 were called by phone and 57 denied participation 
because of lack of time. The assessment was not completed by 12 individuals. Because of a 
Beck Depression Inventory (BDI) score exceeding 18 points, three subjects were excluded. 
Positive urine screening results led to the exclusion of three individuals.   
 
Data attained from 284 subjects were assessed and analysed. Participants were paid for their 
time and effort (15 €/h). Written informed consent to participate in a study assessing cognitive 
functioning was obtained from all subjects. The research protocol was approved by the ethics 
committee (internal review board) of the Medical Faculty of Ludwig-Maximilians University 
(LMU) of Munich, Germany.   
 
Procedure   
 
Subjects were instructed not to take any drugs or alcohol for at least 1 week before the test 
session. This may have a detrimental influence on cognitive performance because the aim of 
this study was to assess the optimal performance level of participants. Smoking was allowed 
to avoid disturbances caused by withdrawal.   
 
All participants underwent the same procedure. Assessment consisted of a single session, 
lasting about 3 h. A testing battery was conducted in two units, with a short break in between. 
During the break, a urine probe was taken to confirm abstinence and then analysed using 
standardised methods by the laboratory at LMU. The probe was tested for cocaine, opiates, 
methadone, cannabis, LSD, amphetamines and barbiturates. Every session was conducted 
double blind. Neuropsychological assessment included diverse tests of memory and attention. 
Tests of executive function and working memory will be reported separately (Piechatzek, et 
al., submitted). Subjects received feedback about their test results at the end of the session. In 
addition, the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was 
administered (WHO ASSIST Working Group, 2002). If substance use was recorded to be 
problematic, a short feedback-based intervention, which involved applying motivational 
interviewing techniques (Rollnick and Bell, 1991), was administered after the 
neuropsychological testing.   
 
Drug-related variables   
 
All participants were interviewed extensively regarding their lifetime substance use. The 
questions are part of the EDSP interview (M-CIDI, Pfister and Wittchen, 1995; DIA-X, 
Wittchen and Pfister, 1997). Questions included in the sections investigating alcohol and drug 
use were based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV) (American Psychiatric Association, 1994) and the International Statistical 
Classification of Diseases, 10th revision (ICD-10) (World Health Organisation, 1993) criteria. 
Some example questions asked on the use of different substances (cannabis, in the examples 
presented here) are as follows:   
 
 Did you ever use cannabis in your life? If yes, when did you start using the substance?   
 Have you stopped using cannabis?   
 On how many occasions did you ever use this substance?   
 
Self-reported frequencies were sampled in categories to assess lifetime use (see Table 3).   
   
 
Assessment of current psychiatric symptoms   
 
BDI (Beck, et al., 1961; German version from Hautzinger, et al., 1994); state–trait anxiety 
inventory (STAISTAISTAISTAI: Spielberger, 1983; German version, Laux, et al., 1981)   
 
To rule out current psychiatric symptoms as a possible factor causing cognitive deficits, 
participants completed the BDI and the STAI. The BDI is a 21-item self-report rating 
inventory measuring characteristic attitudes and symptoms of depression. The STAI consists 
of 20 items assessing state anxiety and another 20 items assessing trait anxiety.   
 
Estimation of intelligence level   
 
Multiple choice vocabulary test (MWTMWTMWTMWT: Lehrl, et al., 1995; German version 
(MWT-B) from Lehrl, 1999)   
 
The MWT-B test was performed to assess the intelligence level of the participants included in 
this study. This test requires participants to select one of five alternative phrases and to mark 
the only alternative that actually exists in the German language. The test is regularly used for 
an estimation of IQ because there is a good correlation with general intelligence measures 
(Lehrl, 1999).   
 
Memory and verbal learning   
 
Logical memory (LM) subtest from the wechsler memory scalerevised (WMS-R: Wechsler, 
1987; German version from Härting, et al., 2003)   
 
Using Wechsler’s standard instructions for the LM subtest, two stories were presented orally 
to subjects, each one followed by an immediate free recall trial. Free recall of both stories was 
again tested after a delay of 30 min. The immediate score reflects the amount of information 
that subjects can recall immediately after hearing the stories. The delayed score reflects the 
amount of information from the two stories that a subject can recall after a 30-min delay.   
 
Rey Auditory-Verbal Learning Test (RAVLTRAVLTRAVLTRAVLT: Rey, 1958; Lezak, 
1976, 1983; German version from Heubrock, 1991)   
 
A 15-word recall list (List A) was presented five times. Subjects were requested to recall as 
many of the words as possible immediately following each presentation (Trials 1–5). All 
responses were noted for subsequent scoring. No time limit was given, and participants were 
allowed to recall all the words in arbitrary order. After Trial 5, a new list of 15 words (List B) 
was presented, and recall was requested immediately following the presentation. After the 
List B trial, participants again recalled List A, but without previous presentation (Trial 6). 
After a 30-min interval, participants recalled List A without previous information (Trial 7). To 
test recognition memory, a written list with 50 words was presented. The list contained the 
words from List A, the words from List B and an additional 20 words that were phonemically 
and/or semantically similar to the words in Lists A and B. The participants were instructed to 
mark the 15 words from List A.   
 
Rey-Osterrieth Complex Figure Test (CFTCFTCFTCFT: Rey, 1941; Osterrieth, 1944)   
 
The CFT reflects the visuo-constructive abilities for the copy part and the nonverbal memory 
abilities for the delayed recall part. First, the participants were required to copy an abstract 
geometrical figure while it is in view (Copy trial). The time needed to finish the copy and the 
qualities of the drawing were recorded, and points were assigned for accuracy and placement 
of each element in the overall design. After a 30-min delay, and without previous information, 
participants were asked to reproduce the geometrical figure from memory. The number of 
details remembered after a 30-min delay was used as an indicator for delayed visual memory 
recall.    
 
Attention   
 
A broad range of attentional measures exists; however, these attentional tasks have not been 
systematically discussed within a theoretical framework of attentional subsystems. As with 
memory, a considerable amount of evidence indicates the existence of different attentional 
subsystems that seem to be neuroanatomically and neuropharmacologically dissociable to a 
certain degree (van Zomeren and Brouwer, 1994; Raz and Buhle, 2006). It has also been 
argued that classical neuropsychological paradigms may be relatively insensitive to 
performance decrements induced by chronic cannabis abuse (Solowij, 1998).   
 
The current test selection is based on a multidimensional attention model devised by van 
Zomeren and Brouwer (1994). Their model broadly distinguishes between different aspects of 
attention, which include the following: 1) intensity, as tapped by alertness (tonic alertness and 
phasic alertness) and vigilance tests; 2) selectivity, as exemplified by the ability to focus 
attention on specific stimuli (selective attention); 3) the ability to distribute attentional 
capacity over several information sources (divided attention) and 4) the ability to change the 
focus of attention deliberately (flexibility).   
 
Test for attentional performance (TAP, Version 1.7: Zimmermann and Fimm, 2002)   
 
This test consists of a battery of attentional subtests based on reaction time. Subjects were 
instructed to perform the tasks as quickly as possible while maintaining a high level of 
accuracy. Each of the tests was introduced with a number of test trials to ensure 
comprehension of the task demands. For each task, reaction time measures (mean of the 
correct reactions), the number of errors (false reactions) and the number of omissions (no 
reactions) were recorded.   
 
TAP – alertness   
 
A simple reaction time task measures response readiness to a simple visual target (a cross of 
about 1.2 × 1.8 cm) appearing on a computer screen, which is either preceded (phasic 
alertness) or not preceded (tonic alertness) by a warning acoustic signal. The tonic alertness 
condition measures an intrinsic alertness, indicating cognitive control of alertness in the 
absence of an external cue, whereas phasic alertness relies on facilitating external cues. The 
test was carried out via an ABBA design (A: block of trials without an acoustic warning 
signal; B: block of trials with an acoustic warning signal), with 20 stimuli per condition. For 
the final analysis, the tonic and the phasic parts of the attention measurements were separated.   
 
TAP – incompatibility   
 
Arrows were briefly presented on the left or the right side of a central fixation point in a 
random manner. The arrows could point to either the right or the left side. Subjects had to 
respond to the direction of the arrow as quickly as possible by pressing a complementary 
response key, with a left-hand key corresponding to arrows pointing to the left, and a right-
hand key corresponding to arrows pointing to the right. Subjects had to suppress interfering 
tendencies to orient to the side of the presentation. A total of 57 trials were presented.   
 
TAP – flexibility   
 
This task assesses the ability to shift the focus of attention flexibly between stimulus 
dimensions. Two competing stimuli (one digit and one letter; each 2.0 × 2.0 cm) were 
presented simultaneously, one on the left and one on the right side of the screen. Subjects had 
to indicate the position of a current target stimulus (digit or letter) by pressing a corresponding 
left-hand or right-hand response button. The target stimulus alternates from trial to trial so that 
subjects had to shift the focus of attention continuously. Depending on the position of the 
stimuli, the change of target stimulus could be associated with an alternation of the side of the 
correct reaction or the response hand could remain the same. The latter cases were more 
complicated, as indicated by slower average reaction times and a higher number of errors. For 
data analysis, results were separated into trials with hand changing (critical stimuli was not on 
the same side as in the previous trial) and trials without hand changing (critical stimuli was on 
the same side as in the previous trial). A total of 100 trials were presented.   
 
TAP – divided attention   
 
This dual task requires attention to visual and acoustic stimuli presented simultaneously. In 
the visual task, random spatial arrangements of crosses appeared on the screen (of about 9.5 × 
11.0 cm), and subjects had to react as quickly as possible when four of these crosses formed a 
square. In the acoustic domain, which was presented in parallel, participants had to detect 
irregularities within an otherwise alternating sequence of high and low tones (i.e., successions 
of two high or two low tones). Results for reaction time and error measures of the visual and 
acoustic domains were separated.   
 
TAP – vigilance   
 
Two small rectangles (of about 1.2 × 2.4 cm), one situated on top of the other, were presented 
in the centre of the computer screen. The rectangles were filled alternately with a pattern. 
Subjects were requested to press a response key when the pattern filled the same rectangle 
twice in succession. The time intervals between these target stimuli were irregular, and the 
frequency of their appearance was low. The duration of the test was 15 min. A total of about 
600 stimuli were presented. For data analyses, the whole duration of the task was separated 
into three parts (part one: 1–5 min; part two: 6–10 min; part three: 11–15 min).   
 
Self-reported cognitive deficits   
 
The cognitive failures questionnaire (CFQCFQCFQCFQ: Broadbent, et al., 1982; German 
version from Klumb, 1995)   
 
To complement laboratory measures of attentional and memory function with subjective data, 
the CFQ was conducted. The German version of the CFQ is a 32-item self-report inventory 
that inquires about a person’s failures in attention, memory, perception and motor function 
over the past 6 months (e.g., ‘Do you bump into people?’ ‘Do you find that you forget 
appointments?’). The response format uses a 5-point scale (0 = never, 4 = always). The score 
is a weighted sum of all items.   
 
Statistical analysis   
 
All data were analysed using the Statistical Package for the Social Sciences version 13.0 for 
Windows (SPSS, Inc. Chicago, Illinois, USA). Multiple linear regression models were used to 
analyse the relationships between predictors and dependent measures. The model included 
variables for the lifetime use (occasions) of the three substance classes (ecstasy, cannabis and 
alcohol), as well as the control variables (sex, verbal IQ and age) as predictors. Using a 
hierarchical approach, the background variables [sex, age (Davies, et al., 1992) and 
intelligence (Anderson, 1992)] were included in the first step. The drug use variables could 
then be included in the second step so that the significance of the increment in the R2 value 
could be evaluated.   
 
To conduct regression analyses, original categorical data of ecstasy and cannabis use were 
transformed into metric data by using the midpoint of each category. For the category of more 
than 365 times of cannabis consumption, it was not possible to transform data by using the 
midpoint of the category. To eliminate bias caused by extreme values, the trimmed mean was 
used to estimate the midpoint of the highest consumption categories. Because the alcohol use 
variable was already assessed in metric, no transformation was needed.   
 
First, the correlations between predictors were calculated. To prevent interpretation problems 
because of multicollinearity, a forward approach for multiple linear regression analysis was 
chosen. The inclusion criterion was P < 5%, and the exclusion criterion was P > 10%.   
 
The distribution of the raw data of lifetime use for the three substance classes was skewed to 
the right. A logarithmic transformation (log10) was performed to reduce the violation of the 
normal distribution. The logarithmic function is not defined for zero. To complete the 
analysis, ‘1’ was added to the raw data before the logarithmic transformation.   
 
Effect sizes were estimated based on conventions put forth by Cohen (1988), suggesting 
‘small’ effects with R²adj ≥ 0.02, ‘medium’ effects with R²adj ≥ 0.13 and ‘large’ effects with 
R²adj ≥ 0.26.   
 
Demographics and current psychiatric symptoms   
 
A total of 284 subjects were tested, 181 men and 103 women. Frequencies for sex are 
described in Table 12. The mean age was 25.83 years (SD = 3.08), with a range of 22–34 
years. More than 75% (214 subjects) of the subjects had a university-entrance diploma or an 
even higher level of education. Table 2 presents the scores of the IQ, depression and anxiety 
measures.   
 
Substance use   
 
The lifetime frequencies of ecstasy and cannabis consumption are presented in Table 3. 
Ecstasy consumption among the subjects was predominantly low, with only several occasions 
of ecstasy intake. Only nine subjects used ecstasy on more than 50 occasions in their lifetime. 
Of the tested sample, 43% never used cannabis, more than 38% used it on fewer than 365 
occasions in their lifetime and up to 18% used cannabis more than 365 times. The categories 
are not identical to those described in publications investigating the full EDSP samples.   
 
The alcohol indices (estimate of overall alcohol use) were derived from the mean amount of 
alcohol and from the frequency of alcohol intake during the period of heaviest lifetime use. 
To compare the different effects of alcohol on women and men, the amount consumed by 
women was multiplied by a factor of 1.5 (Uhl, et al., 2001). The mean of the tested population 
was 28.3 g/day, with an SD of 34.8 g (0–270 g/day). This index value is most likely an 
overestimation of the real amount because the estimations are based on the heaviest reported 
period in lifetime use. Because the other substances are not fluid based and similar sex effects 
have not been established, we refrained from similar adaptations for the other substances.   
 
 
Results   
 
Attributing specific effects to specific substances is a problem because multiple substance use 
is the rule. To account for multiple substance use and to adjust for other major confounders, 
the analysis is based on linear regression models.   
 
Predictor variables and correlations   
 
The amounts of ecstasy, cannabis and alcohol use were defined as predictor variables. Sex, 
age and IQ were included as further control variables or background variables. The 
intercorrelations of the mentioned variables are shown in Table 4. A correlation matrix with 
correlations for the predictors against each of the dependent variables, means and standard 
deviations for each variable are shown in Table 11 and Table 13.   
 
Background variables   
 
In 11 of the 24 regression models, sex was a significant predictor. As a predictor, IQ was 
significant in 10 of the 24 regression models. Age was a significant predictor in 7 of the 24 
regression analysis models (α = 0.05) (for details, see Tables 5–10).   
 
Memory and verbal learning   
 
Logical memory   
 
As shown in Table 5, lifetime cannabis consumption was a significant predictor of 
performance for the immediate recall (R2 (change) = 0.019; df = 1; P < 0.016) and the 
delayed recall (R2 (change) = 0.020; df = 1; P < 0.014) of LM.   
 
Rey Auditory-Verbal Learning Test   
 
The linear regression results for the RAVLT are shown in Table 6. For the first delayed recall 
of List A (List A, 6), ecstasy consumption was a significant predictor of performance (R2 
(change) = 0.025; df = 1; P < 0.005).   
 
Rey-Osterrieth Complex Figure Test   
 
Results for time needed and accuracy data are shown in Table 7. For the CFT copy task, 
ecstasy consumption was a significant predictor of performance (R2 (change) = 0.014; df = 1; 
P < 0.048).   
 
Attention   
 
Reaction time measures   
 
Results of the forward linear regression model for the median reaction time measures in tonic 
and phasic alertness, selective attention, flexibility, divided attention and vigilance are shown 
in Table 8. None of the tested substances reached the level of significance.   
 
Error measures   
 
The results of the linear regression models for the number of errors and omissions in the tonic 
and phasic alertness, selective attention, flexibility, divided attention and vigilance tasks are 
shown in Table 9. For the number of omissions in the tonic alertness task (R2 (change) = 
0.028; df = 1; P < 0.005), cannabis was the significant predictor. In the phasic alertness task 
(R2 (change) = 0.023; df = 1; P < 0.011, the selective attention task (R2 (change) = 0.030; df 
= 1; P < 0.004 and the vigilance task score (R2 (change) = 0.030; df = 1; P < 0.004), ecstasy 
was the significant predictor.   
 
Cognitive Failures   
 
Questionnaire Cannabis was the significant predictor of the outcome in the CFQ score (R2 
(change) = 0.054; df = 1; P < 0.001). A high amount of cannabis use was predictive of more 
self-experienced failures in everyday life. Further details are described in Table 10.   
 
 
Discussion   
 
The aim of the present investigation was to assess the memory and attentional performance of 
subjects with varying degrees of drug-use experience. Participants were selected from a 
community-based representative sample being investigated for a large-scale epidemiological 
study. This subsample consisted of 284 subjects, ranging from 22 to 34 years, with different 
levels of drug abuse, as indicated by data from previous assessments. In general, the subjects 
reported moderate levels of drug use experience, with only a limited number of participants 
reporting regular and extensive use of illicit substances. Published studies examining 
cognition in substance users have regularly relied on self-referred participants with more 
extensive drug-use histories, thus focussing on high-risk populations (Block and Ghoneim, 
1993; Fletcher, et al., 1996; Parrott, et al., 1998; Schifano, et al., 1998; McCann, et al., 1999; 
Morgan, 1999; Rodgers, 2000; Croft, et al., 2001; Pope, et al., 2001; Gruber, et al., 2003; 
McCardle, et al., 2004; Yip and Lee, 2005). On the contrary, data obtained from 
epidemiological samples may create a picture that more closely resembles a population-based 
picture of possible detrimental effects associated with substance abuse.   
 
Participants were informed that cognitive performance in young adults would be assessed. 
Furthermore, they knew that they would be paid for their time and provided with short 
feedback about their performance at the end of testing. On the contrary to many previous 
studies, subjects had no a priori knowledge that drug use was the critical condition for their 
selection into the present subsample. In addition, the testing psychologists were blind to the 
subjects’ drug-use history. Thus, test results should be less confounded by subjective 
expectations and sample biases, which have influenced studies reported to date.   
 
Even though subjects were subsampled from a regionally representative sample of young 
adults, demographic data concerning educational background and estimations of intelligence 
indicate that the sample showed comparably high levels of cognitive functioning. It is quite 
possible that higher levels of cognitive function are helpful in compensating for the 
detrimental effects of factors that reduce brain functions, as suggested by concepts of cerebral 
reserve capacity (‘functional reserve’: Fein and Di Sclafani, 2004). In fact, several of the 
parameters showed an additional predictive relationship with IQ. Therefore, the associations 
between cognitive function and drug abuse variables determined in this population possibly 
represent the lower boundaries of the empirical associations that may be found in more 
heterogeneous populations, with respect to levels of cognitive function.   
 
Memory and verbal learning   
 
Reduced ability to recall a short passage of prose immediately and after a delay was 
associated with increasing lifetime use of cannabis. Increasing cannabis lifetime use was also 
associated with lower scores for the immediate, as well as delayed, recall. These findings are 
in line with the results of a meta-analytic study showing the small effects of cannabis use on 
memory functions (Grant, et al., 2003).   
 
When the competencies of repeated list learning were assessed, only the results obtained for 
the recall of List A after the interfering List B were associated with ecstasy use. A possible 
explanation may be the different form of task presentation. Whereas the RAVLT task was 
presented five times, the LM task was presented only once. In terms of visual memory 
performance, no relation between substance use history and nonverbal memory was found.   
 
Lower scores in memory and verbal learning performance are the most common findings in 
heavy users of illegal substances. Because the assessed sample comprised young and well-
educated subjects with high intelligence levels, drug use was not likely to cause massive 
cognitive deficits in these subjects. Thus, the small effect sizes are not surprising. This 
emerging pattern of reduced memory and verbal learning performance associated with drug 
use is consistent with a number of studies showing memory impairment to be the most 
consistent deficit associated with ecstasy and cannabis use (Verbaten, 2003; Dafters, 2006; 
Fisk, et al., 2006). Ecstasy use among subjects in this study was almost always combined with 
cannabis use, as has been the case in previous studies.   
 
Attention   
 
In three of five aspects of attention assessed, an association between drug use and error 
frequency was detected. Small effects were found even for aspects of tonic and phasic 
alertness, selective attention and vigilance. All effects were in the same direction. An 
increasing amount of substance use was associated with higher numbers of errors or 
omissions. No association was detected between reaction time measures and substance use. In 
general, reaction time was associated with socio-demographic factors, such as sex and age.   
 
Some evidence for slower reaction times and more errors has been reported in the literature, 
specifically for complex attentional tasks (McCann, et al., 1998; Gouzoulis-Mayfrank, et al., 
2000; Fox, et al., 2001a,b). Average reaction times in combination with a higher incidence of 
errors may be interpreted as a higher frequency of lapses of attention (i.e., short-term losses of 
attentional control). These participants may experience more difficulties exerting deliberate 
control over their level of attention (Raz and Buhle, 2006). Such lapses of attention may 
become more apparent under sustained attention conditions.   
 
Subjective memory complaints   
 
In this study, cannabis use was associated with higher scores in self-reported cognitive 
deficits in everyday life, whereas ecstasy use failed to become a significant predictor. In an 
Internet survey, Rodgers, et al. (2001) showed that cannabis use was associated with 
subjective short-term memory problems, whereas ecstasy use was more related to subjective 
long-term memory problems. In an earlier study, Rodgers (2000) reported that ecstasy use 
was not associated with self-reported deficits on the CFQ. Given the quite low lifetime doses 
of the previous ecstasy consumers, these cognitive findings would not yet have an impact on 
daily life activities. The cognitive failure reported by cannabis users may be attributed to the 
prolonged pharmacological effects of cannabis.   
 
In summary, we found ecstasy and cannabis use to be associated with results of the verbal 
memory tasks. List learning was not associated with drug use; however, the capacity to 
reproduce a learned list after an interfering list seemed to be lower in relation to ecstasy use. 
The error frequencies in three of five attentional tasks were also associated with the use of 
ecstasy and cannabis. Reaction time measures for different tasks were unrelated to substance 
use. Alcohol use did not show any relation to test results.   
 
Limitations   
 
There are some limitations that have to be considered when interpreting the findings of this 
study. A causal interpretation of the correlative relationships is hampered by the existence of 
potential residual confounders. The nature of this design also makes it impossible to make an 
inference on the temporal relationship between cognitive performance and drug abuse.   
 
With 24 regressions analysed, the family-wise error rate for each predictor is approximately 
0.70. An adjusted α-value of 0.002 would reduce the family-wise error rate to roughly 0.05. 
This indicates that findings might be chance findings, and need to be replicated, before solid 
conclusions can be drawn.   
 
As previously pointed out by other authors (Schuster, et al., 1998; Gouzoulis-Mayfrank and 
Daumann, 2006), it is difficult to separate the effects of the different substances used by the 
participants. Given that distinct groups are not available (and if available, these groups would 
not be considered representative), we used regression analysis to separate statistically the 
distinct effects.   
 
Neuropsychological testing was developed to assess differences after brain lesions. It remains 
open as to how useful these tests are in detecting subtle deficits, such as the ones mentioned in 
this study. The purpose of this project was to explore the possible effects of moderate 
substance use in young adults in a population-based sample.   
 
As already mentioned, higher-educated subjects were more likely to participate in that study 
than less-educated subjects. Participants of this study have high intelligence levels. These 
subjects may also have good compensation strategies that facilitate cognitive outcome, thus 
masking the detrimental effects of drug abuse that may be detectable in less-educated 
subjects.   
 
Intensity of use and/or time since last substance use was not systematically manipulated in 
this study and could be relevant factors for cognitive outcome, specifically because studies 
have reported persistent effects of cannabis during initial abstinence. By interviewing patients, 
using alcohol breathalysers and performing urine analysis, we made sure that none of the 
participants was intoxicated. Subjects were allowed to smoke cigarettes during the time before 
the test session. In this study, we, thus, adopted the reported approach to tobacco smoking, 
smoking history was not quantified.   
 
Despite these limitations, the results provide evidence that even limited illegal drug use may 
have a subtle influence on cognition in otherwise healthy and well-educated young people. 
Further investigations are necessary to increase our knowledge of the consequences of 
substance use in young users who are not seeking treatment. Longitudinal investigations 
would be most helpful in verifying the existence of a causal relationship between substance 
abuse and decrements in cognitive function, and in ruling out premorbid factors as possible 
explanations.   
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